For reasons that remain unclear, kidney cancer risk was higher in users of GLP-1 agonists, particularly those under 65 and ...

Serena Williams has been taking a GLP-1 medication to help with her recent weight loss, she revealed for the first time in an ...

With 23 Grand Slam singles titles and four Olympic gold medals, Serena Williams is undeniably a superathlete. But the 43-year ...

Originally appeared on E! Online Serena Williams is serving up an honest look into her weight ...

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of ...

Studies have found that semaglutide, the chemical in Ozempic, reduced alcohol intake, binge drinking and relapse ...

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...

Serena Williams recently detailed her weight loss journey, sharing that she lost 31 pounds with the assistance of a GLP-1 ...

GLP-1 receptor agonists may reduce cancer risk among people with obesity or overweight, according to retrospective study results.Adults who used GLP-1 medications exhibited a statistically significant ...

GLP-1 receptor agonists may outperform metformin in lowering the risk for dementia, particularly Alzheimer’s disease and other nonvascular types, in patients with type 2 diabetes.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.